Aztiq
David Olafsson has a background in finance and mathematics, with experience in risk management and corporate development. David currently serves as the Managing Director at Aztiq, previously holding managerial roles at Alvogen and Landsbankinn. Olafsson also worked in interest rate derivatives at Landsbanki and holds a MS in Financial Mathematics from The University of Edinburgh.
This person is not in any teams
This person is not in any offices
Aztiq
Aztiq is a long-term investment fund, based in Iceland, focused on pharmaceuticals, real estate, arts & culture, and numerous community projects in Iceland and internationally. See Icelandic below. The shareholder base consists of individual investors, as well as large international investment funds. https://aztiqfinance.com/ Aztiq’s largest assets are pharmaceutical companies Alvogen and Alvotech and the real estate company Saemundur. Aztiq is in the process of constructing a high-tech biologic center in the UI (University of Iceland) Science Park in Vatnsmyri, Reykjavik, which will double the size of the fund’s pharmaceutical facilities in Iceland. Additionally, Aztiq is a major shareholder in Þorpið (reads Thorpid) – an ecological community development project, in partnership with the City of Reykjavik. Aztiq's shareholder base consists of individual investors, led by Robert Wessman, as well as large international investment funds. Icelandic: Aztiq er virkur langtímafjárfestir hérlendis sem erlendis, meðal annars í lyfjaiðnaði, fasteignum, menningarauði og samfélagsverkefnum. Fjárfestingarhópur Aztiq saman stendur af öflugum íslenskum og erlendum einstaklingum sem og alþjóðlegum fjárfestingarsjóðum undir stjórn Róberts Wessman. Stærstu eignir Aztiq eru í lyfjafyrirtækjunum Alvogen, Alvotech, Lotus, Almatica og Adalvo og í fasteignafélögunum Hrjáf, Sæmundi og Eyjólfi. Astiq stendur að uppbyggingu hátækniseturs í Vatnsmýri en áætluð verklok eru í árslok 2022. Þá er Aztiq stór hluthafi í Þorpinu – vistfélagi í samstarfi við Reykjavíkurborg.